CJC-1295 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability. It is researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects. Common dosages range from 100-300 mcg administered 1-3 times daily, typically before bed.
What Is CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability. Also known as CJC-1295, Mod GRF 1-29, CJC-1295 no DAC, it has been studied for its potential effects on increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.
The 'no DAC' version is preferred over CJC-1295 DAC because it preserves natural pulsatile GH release rather than creating a sustained elevation that can desensitize receptors and suppress feedback loops. In the research community, CJC-1295 has gained attention for its distinctive profile.
How Does CJC-1295 Work?
CJC-1295 binds to GHRH receptors on anterior pituitary somatotrophs, stimulating growth hormone synthesis and pulsatile secretion through the cAMP-PKA signaling cascade. The 'no DAC' version has a shorter half-life, resulting in more natural GH pulses that mimic the body's endogenous rhythm rather than creating sustained supraphysiological levels.
This multi-pathway activity helps explain why CJC-1295 shows potential across several different applications.
What Does the Research Say About CJC-1295?
Clinical research demonstrates significant increases in GH and IGF-1 levels in human subjects. Studies show improved body composition with increased lean mass and reduced body fat, particularly when combined with GHRP peptides like Ipamorelin.
Researchers should consult the latest peer-reviewed literature for the most current findings.
What Is the Recommended CJC-1295 Dosage?
Standard CJC-1295 dosing: 100-300 mcg, administered 1-3 times daily, typically before bed via subcutaneous injection.
Half-life: ~30 minutes (no DAC), ~8 days (with DAC). Cycle length: 8-12 weeks, often paired with Ipamorelin.
Use our peptide dosing calculator for exact reconstitution ratios.
Calculate Your CJC-1295 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295.
Open Calculator →What Are the Side Effects of CJC-1295?
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use.
CJC-1295 is not fda-approved. research chemical status. banned by wada.
Can You Stack CJC-1295 With Other Peptides?
The gold standard stack is CJC-1295 + Ipamorelin — GHRH + GHRP together produce GH pulses far greater than either alone, through synergistic pituitary stimulation via two distinct receptor pathways.
What Is the Bottom Line on CJC-1295?
CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analog researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects. Standard protocols use 100-300 mcg 1-3 times daily, typically before bed for 8-12 weeks, often paired with Ipamorelin.
Source from COA-tested vendors. Read our beginner's guide for more, or use the dosing calculator to plan your protocol.
Complete Guide
CJC-1295 : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 Dosage Guide
- CJC-1295 Benefits
- CJC-1295 Side Effects
- CJC-1295 Stacking Guide
- CJC-1295 Cycle Guide
- CJC-1295 Research
Research-Grade Sourcing
If you're going to research CJC-1295, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability. It is researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.
What is the recommended CJC-1295 dosage?
Common dosages: 100-300 mcg administered 1-3 times daily, typically before bed via subcutaneous injection. Cycle length: 8-12 weeks, often paired with Ipamorelin. Half-life: ~30 minutes (no DAC), ~8 days (with DAC). Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295?
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use.
Is CJC-1295 safe?
CJC-1295 has shown a preliminary safety profile in research. Not FDA-approved. Research chemical status. Banned by WADA. All research should follow appropriate safety protocols.